ES3060000T3 - Stable medicinal cannabidiol compositions - Google Patents

Stable medicinal cannabidiol compositions

Info

Publication number
ES3060000T3
ES3060000T3 ES19945356T ES19945356T ES3060000T3 ES 3060000 T3 ES3060000 T3 ES 3060000T3 ES 19945356 T ES19945356 T ES 19945356T ES 19945356 T ES19945356 T ES 19945356T ES 3060000 T3 ES3060000 T3 ES 3060000T3
Authority
ES
Spain
Prior art keywords
composition
cannabidiol
stable medicinal
cbd
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19945356T
Other languages
English (en)
Inventor
Blagoja Ristevski
Anthony Ernest Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiol Therapeutics Inc
Original Assignee
Cardiol Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiol Therapeutics Inc filed Critical Cardiol Therapeutics Inc
Application granted granted Critical
Publication of ES3060000T3 publication Critical patent/ES3060000T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición estable de cannabidiol medicinal para administración oral, que comprende cannabidiol sintético (CBD) con una pureza de al menos 99,8 %, preferiblemente de al menos 99,9 %, junto con betacariofileno (BCP), que actúa como disolvente y antioxidante. La composición contiene además al menos un disolvente lipofílico (p. ej., triglicéridos de cadena media (MCT) y aceite de coco) y al menos un antioxidante (p. ej., alfa-tocoferol (vitamina E)). La composición está prácticamente libre de otros cannabinoides, terpenos, disolventes e ingredientes farmacéuticamente activos. Asimismo, se describen métodos para la elaboración y estabilización de CBD en una composición oral. (Traducción automática con Google Translate, sin valor legal)
ES19945356T 2019-09-09 2019-09-09 Stable medicinal cannabidiol compositions Active ES3060000T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2019/051259 WO2021046628A1 (en) 2019-09-09 2019-09-09 Stable medicinal cannabidiol compositions

Publications (1)

Publication Number Publication Date
ES3060000T3 true ES3060000T3 (en) 2026-03-24

Family

ID=74867096

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19945356T Active ES3060000T3 (en) 2019-09-09 2019-09-09 Stable medicinal cannabidiol compositions

Country Status (9)

Country Link
US (1) US20220347118A1 (es)
EP (1) EP4028059B1 (es)
JP (1) JP7487292B2 (es)
AU (1) AU2019465548B2 (es)
BR (1) BR112022002409A2 (es)
CA (1) CA3152020C (es)
ES (1) ES3060000T3 (es)
MX (1) MX2022002548A (es)
WO (1) WO2021046628A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116583272A (zh) 2020-10-19 2023-08-11 埃维科生物技术有限公司 包含生育酚磷酸酯和长链甘油三酯或长链脂肪酸的口服大麻素制剂
WO2022082257A1 (en) 2020-10-19 2022-04-28 Avecho Biotechnology Limited Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
EP4255494A4 (en) * 2020-12-07 2024-08-07 Cardiol Therapeutics Inc. STABLE ORAL CANNABIDIOL COMPOSITIONS
JP2022164537A (ja) * 2021-04-16 2022-10-27 株式会社東洋新薬 経口組成物
CN113480555B (zh) * 2021-08-11 2022-10-18 西北农林科技大学 一种含3,7-二氧杂双环[3,3,0]辛烷结构的木脂素类化合物及其制备方法和应用
UY39943A (es) * 2021-09-14 2023-03-31 Sunsho Pharmaceutical Co Ltd Composición que contiene cariofileno
US20240008514A1 (en) * 2022-07-05 2024-01-11 Fertin Pharma A/S Cannabinoid Lipid Premixture
US20260108540A1 (en) * 2022-10-12 2026-04-23 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol
CN116139111A (zh) * 2022-12-06 2023-05-23 黑龙江哈工智慧汉麻科技有限责任公司 一种辅助治疗睡眠障碍的大麻二酚风味油剂及其制备方法
WO2024155178A1 (ko) * 2023-01-20 2024-07-25 (주)인벤티지랩 칸나비디올을 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
WO2016147186A1 (en) * 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CA2986268C (en) 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
BR102015024165A2 (pt) 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
US20190060300A1 (en) * 2016-03-04 2019-02-28 Sharon Anavi-Goffer Self-Emulsifying Compositions of CB2 Receptor Modulators
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
CA3062814C (en) 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations
CA3065167A1 (en) * 2017-05-31 2018-12-06 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
CA3080468A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Cannabinoid formulations

Also Published As

Publication number Publication date
JP7487292B2 (ja) 2024-05-20
MX2022002548A (es) 2022-03-22
EP4028059A1 (en) 2022-07-20
CA3152020C (en) 2024-03-26
JP2022552056A (ja) 2022-12-15
BR112022002409A2 (pt) 2022-04-26
EP4028059B1 (en) 2025-12-24
EP4028059C0 (en) 2025-12-24
AU2019465548A1 (en) 2022-03-03
US20220347118A1 (en) 2022-11-03
WO2021046628A1 (en) 2021-03-18
EP4028059A4 (en) 2023-05-24
AU2019465548B2 (en) 2025-12-11
CA3152020A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
ES3060000T3 (en) Stable medicinal cannabidiol compositions
ES3056133T3 (en) Method for selective extraction of cannabinoids from a plant source
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
US9474727B2 (en) Pharmaceutical compositions of curcumin
US20190307719A1 (en) Cannabis composition
AR078159A1 (es) Composicion que contiene palmitoil-etanolamida ultra-micronizada .metodo. compuesto.forma polimorfica.
CA2589993A1 (en) Room-temperature stable dronabinol formulations
BR102015024165A2 (pt) composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
DE102010050570A1 (de) Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
RU2011119796A (ru) Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
UY30100A1 (es) Una formulacion farmacéutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubilizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
ECSP045060A (es) Nuevas formulaciones analogas de ciclosporina
PE20071067A1 (es) Composiciones de rapamicina y cci-779 y metodo para su preparacion
BR112019014985A8 (pt) Composição estável de ingrediente ativo lipossolúvel, microcápsula e processo de preparação e uso da mesma
CL2024003642A1 (es) Composiciones veterinarias palatables con antiparasitarios.
AR118823A1 (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa
AR078785A1 (es) Formulaciones de bazedoxifeno con antioxidantes
US20220241199A1 (en) Cannabinoid emulsion composition and method of manufacture
AR037687A1 (es) Composiciones farmaceuticas a base de derivados de azetidina
MX2023006686A (es) Composiciones orales estables de cannabidiol.
CO4790151A1 (es) COMPOSICIONES QUE COMPRENDEN UN INHIBIDOR DE LA PROTEASA DEL VIH COMO VX478 Y UN COMPUESTO DE VITAMINA E sOLUBLE EN AGUA COMO VITAMINA E - TPGS
PE20220942A1 (es) COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO
AR045996A1 (es) Formulaciones semi-solidas para la administracion oral de taxoides
JP7086597B2 (ja) 外用組成物